Free Trial

Agios Pharmaceuticals (AGIO) SEC Filings & 10K Form

Agios Pharmaceuticals logo
$30.76 -1.55 (-4.80%)
Closing price 03/25/2025 04:00 PM Eastern
Extended Trading
$30.67 -0.09 (-0.29%)
As of 03/25/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Agios Pharmaceuticals SEC Filings

DateFilerForm TypeView
03/07/2025
3:15 PM
Agios Pharmaceuticals (Issuer)
Viswanadhan Krishnan (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
03/07/2025
3:18 PM
Agios Pharmaceuticals (Issuer)
Viswanadhan Krishnan (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2025
4:27 PM
Agios Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/04/2025
3:12 PM
Agios Pharmaceuticals (Issuer)
Milanova Tsveta (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/03/2025
3:42 PM
Agios Pharmaceuticals (Subject)
Burns James William (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:44 PM
Agios Pharmaceuticals (Subject)
Gheuens Sarah (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:46 PM
Agios Pharmaceuticals (Subject)
Goff Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:49 PM
Agios Pharmaceuticals (Subject)
Jones Cecilia (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/03/2025
3:50 PM
Agios Pharmaceuticals (Subject)
Milanova Tsveta (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/14/2025
1:35 PM
Agios Pharmaceuticals (Subject)
BB BIOTECH AG (Filed by)
Form SCHEDULE 13G/A
02/13/2025
8:26 AM
Agios Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/13/2025
5:32 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2025
5:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/04/2025
11:02 AM
Agios Pharmaceuticals (Subject)
Farallon Capital Partners, L.P. (Filed by)
Form SCHEDULE 13G/A
01/13/2025
6:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
4:05 PM
Agios Pharmaceuticals (Issuer)
Milanova Tsveta (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
5:36 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2024
3:14 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/08/2024
3:17 PM
Agios Pharmaceuticals (Subject)
Ballal Rahul D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/08/2024
1:40 PM
Agios Pharmaceuticals (Subject)
Farallon Capital Partners, L.P. (Filed by)
Form SC 13G/A
10/31/2024
8:20 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/31/2024
5:56 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2024
3:15 PM
Agios Pharmaceuticals (Issuer)
Jones Cecilia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:12 PM
Agios Pharmaceuticals (Issuer)
Smith Cynthia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
3:15 PM
Agios Pharmaceuticals (Issuer)
Ballal Rahul D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/12/2024
4:15 PM
Agios Pharmaceuticals (Issuer)
Goff Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/01/2024
8:49 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2024
6:03 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2024
3:30 PM
Agios Pharmaceuticals (Issuer)
Gheuens Sarah (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:06 PM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/17/2024
4:29 PM
Agios Pharmaceuticals (Issuer)
Schenkein David P (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:31 PM
Agios Pharmaceuticals (Issuer)
FOUSE JACQUALYN A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:32 PM
Agios Pharmaceuticals (Issuer)
Foster-Cheek Kaye I (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:13 PM
Agios Pharmaceuticals (Issuer)
CAPELLO JEFFREY D (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:15 PM
Agios Pharmaceuticals (Issuer)
Owen Catherine E. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:18 PM
Agios Pharmaceuticals (Issuer)
Scadden David (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:19 PM
Agios Pharmaceuticals (Issuer)
Ho Maykin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:20 PM
Agios Pharmaceuticals (Issuer)
Smith Cynthia (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2024
4:22 PM
Agios Pharmaceuticals (Issuer)
Ballal Rahul D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2024
6:50 PM
Agios Pharmaceuticals (Subject)
Goff Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/05/2024
3:14 PM
Agios Pharmaceuticals (Issuer)
Washburn Theodore James Jr. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars (Ad)

Musk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to help build human colonies on the Red Planet. And here on Earth? Optimus is about to change everything.

There's no time to waste. As far as I can tell, the best way to profit from this project is to make
05/28/2024
6:09 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
8:20 AM
Agios Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2024
6:01 AM
Agios Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/10/2024
3:03 PM
Agios Pharmaceuticals (Issuer)
FOUSE JACQUALYN A (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Remove Ads

Related Companies and Tools


This page (NASDAQ:AGIO) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners